Sign In
Buy HTBX
$2.38
+0 (+0%)
At Close: Aug 17, 2022
Takeda to Present Data at Upcoming Virtual Scientific Congresses, Underscoring Breadth of Oncology Portfolio and Emerging Pipeline
05:00pm, Thursday, 14'th May 2020
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”) today announced that the company will present data from its expanding oncology pipeline...
Merck, Roche, Amgen Stocks React to Release of Cancer-Drug Data
02:46pm, Thursday, 14'th May 2020
The American Society of Clinical Oncology released abstracts of the papers set to be presented at its coming meeting. Analysts and investors are combing through the documents for key developments.
Median overall survival (OS) of 28.7 months for HS-110 in combination with nivolumab in previously treated checkpoint inhibitor naïve non-small cell lung cancer (NSCLC) patients DURHAM, NC / ACCESSWI
Foundation Medicine and Collaborators to Share New Data at ASCO20 Showcasing the Importance of CGP in Informing Cancer Clinical Decision-Making
Breakthrough Innovation in Cancer Care From Merck Pipeline to Be Presented at ASCO 2020
10:23pm, Wednesday, 13'th May 2020
- Results from two studies of BAVENCIO® to be featured in ASCO press briefing
8-K: Turning Point Therapeutics, Inc.
03:19am, Wednesday, 13'th May 2020
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT (EDGAR Online via COMTEX) --
Pursuant to Section 13 or 15(d)...
NovoCure: A Long-Term Hold At A Competitive Price
01:25am, Wednesday, 13'th May 2020
NovoCure is developing and commercialising a novel form of cancer therapy treatment - Tumor Treating Fields - which uses electric fields to disrupt solid tumor
Global Anaplastic Lymphoma Kinase Non Small Cell Lung Cancer Market - Epidemiology Forecast to 2030 - ResearchAndMarkets.com
12:00am, Wednesday, 13'th May 2020
The
NanoString Highlights Recent Publications that Demonstrate the Performance of the GeoMx DSP.
Eli Lilly's Retevmo, And Other News: The Good, Bad And Ugly Of Biopharma
02:48pm, Monday, 11'th May 2020
Eli Lilly's Retevmo gets FDA approval. Arcturus announces positive preclinical data for Covid-19. Quidel's antigen test kit gets FDA approval.
Heat Biologics Provides Clinical Update; Reports Continued Progress Advancing HS-110
12:00pm, Monday, 11'th May 2020
DURHAM, NC / ACCESSWIRE / May 11, 2020 / Heat Biologics, Inc. ("Heat") (HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system,
Sesen Bio Reports First Quarter 2020 Financial Results and Meaningful Progress Towards Demonstrating Analytical Comparability
12:00am, Monday, 11'th May 2020
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, tod
Georgiou, Zephan put more into Orthotouch than it received – BRP
10:01pm, Sunday, 10'th May 2020
'Directors and management of HS companies, B&V and brokers were the only people to make money from the HS schemes.'
Xconomy: Eli Lilly Gets Edge in the “RET” Race With FDA Nod for Cancer Drug
02:33am, Saturday, 09'th May 2020
Eli Lilly received accelerated FDA approval Friday for a drug that treats advanced cancers carrying a certain genetic signature. It’s the latest targeted
Mersana Therapeutics' (MRSN) CEO Anna Protopapas on Q1 2020 Results - Earnings Call Transcript
05:59pm, Friday, 08'th May 2020
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2020 Earnings Conference Call May 8, 2020 08:00 AM ET Company Participants Sarah Carmody – Executive Director-Invest
